Asia Pacific Antibiotic Resistance Market Size & Outlook
Related Markets
Asia Pacific antibiotic resistance market highlights
- The Asia Pacific antibiotic resistance market generated a revenue of USD 2,338.4 million in 2023.
- The market is expected to grow at a CAGR of 6.2% from 2024 to 2030.
- In terms of segment, cuti was the largest revenue generating disease in 2023.
- CDI is the most lucrative disease segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 2,338.4 million |
| Market revenue in 2030 | USD 3,572.2 million |
| Growth rate | 6.2% (CAGR from 2023 to 2030) |
| Largest segment | Cuti |
| Fastest growing segment | CDI |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | CUTI, CDI, ABSSSI, HABP, CABP, CIAI, BSI |
| Key market players worldwide | Melinta Therapeutics, Basilea Pharmaceutica Ltd, Theravance Biopharma Inc, Seres Therapeutics Inc, AbbVie Inc, Merck & Co Inc, Hubsan, Wockhardt, Entasis Therapeutics, Tetraphase Pharmaceuticals, Paratek Pharmaceuticals, Axogen Inc |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 26.8% of the global antibiotic resistance market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,572.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibiotic Resistance Market Scope
Antibiotic Resistance Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Paratek Pharmaceuticals | View profile | 251-500 | Boston, Massachusetts, United States, North America | http://paratekpharma.com/ |
| Tetraphase Pharmaceuticals | View profile | 51-100 | Watertown, Massachusetts, United States, North America | http://tphase.com |
| Entasis Therapeutics | View profile | 51-100 | Waltham, Massachusetts, United States, North America | http://www.entasistx.com/ |
| Wockhardt | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | http://wockhardt.com |
| Hubsan | View profile | 1-10 | Walnut, California, United States, North America | http://hubsan.com |
| Seres Therapeutics Inc | View profile | 233 | 101 Cambridgepark Drive, Cambridge, MA, United States, 02140 | https://www.serestherapeutics.com |
| Theravance Biopharma Inc | View profile | 99 | Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, Cayman Islands, KY1-1104 | https://www.theravance.com |
| Basilea Pharmaceutica Ltd | View profile | 147 | Hegenheimermattweg 167b, Allschwil, Switzerland, 4123 | https://www.basilea.com |
| Melinta Therapeutics | View profile | 101-250 | New Haven, Connecticut, United States, North America | http://melinta.com |
| Axogen Inc | View profile | 428 | 13631 Progress Boulevard, Suite 400, Alachua, FL, United States, 32615 | https://www.axogeninc.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
Asia Pacific antibiotic resistance market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antibiotic resistance market will help companies and investors design strategic landscapes.
Cuti was the largest segment with a revenue share of 24.75% in 2023. Horizon Databook has segmented the Asia Pacific antibiotic resistance market based on cuti, cdi, absssi, habp, cabp, ciai, bsi covering the revenue growth of each sub-segment from 2018 to 2030.
- Asia Pacific Antibiotic Resistance Disease Outlook (Revenue, USD Million, 2018-2030)
- HABP
- cIAI
- CDI
- ABSSSI
- BSI
- cUTI
- CABP
- Asia Pacific Antibiotic Resistance Pathogen Outlook (Revenue, USD Million, 2018-2030)
- A. baumannii
- H. influenzae
- Enterococcus fecium
- CDI
- klebsiella pneumoniae
- S. aureus
- E.coli
- P. aeruginosa
- Strep. Pneumoniae
- Asia Pacific Antibiotic Resistance Drug Class Outlook (Revenue, USD Million, 2018-2030)
- Tetracyclines
- Combination therapies
- Other drug classes
- Cephalosporins
- Oxazolidinones
- Lipoglycopeptides
- Asia Pacific Antibiotic Resistance Mechanism of Action Outlook (Revenue, USD Million, 2018-2030)
- Protein Synthesis Inhibitors
- Cell Wall Synthesis Inhibitors
- RNA Synthesis Inhibitors
- DNA Synthesis Inhibitors
- Other mechanism of actions
- Asia Pacific Antibiotic Resistance Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Reasons to subscribe to Asia Pacific antibiotic resistance market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific antibiotic resistance market databook
-
Our clientele includes a mix of antibiotic resistance market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific antibiotic resistance market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific antibiotic resistance market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific antibiotic resistance market size, by country, 2018-2030 (US$M)
Asia Pacific Antibiotic Resistance Market Outlook Share, 2023 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
